USANA Health Sciences, Inc. — Form 10-K Summary
Reporting period: The filing covers the fiscal year ended December 29, 2012 (52 weeks), not 2011 Q4 as stated in the request metadata. It was filed March 11, 2013. USANA develops and sells nutritional and personal-care products through direct selling in 18 markets; 76.5% of 2012 sales were outside the United States.
Financial performance and position
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Net sales | $648.7 million | $581.9 million |
| Gross profit / margin | $532.9 million / 82.1% | $480.2 million / 82.5% |
| Operating earnings / margin | $98.2 million / 15.1% | $77.3 million / 13.2% |
| Net earnings / margin | $66.4 million / 10.2% | $50.8 million / 8.6% |
| Diluted EPS | $4.45 | $3.26 |
| Operating cash flow | $92.8 million | $70.1 million |
- Sales rose 11.5%; net earnings increased 30.9%. Diluted EPS rose 36.5%, aided by earnings growth and share repurchases.
- Gross margin declined 0.4 percentage points, attributed mainly to higher raw-material costs, production inefficiencies during personalization/rebranding, and sales mix. Lower Associate incentives and operating expense leverage contributed to improved operating and net margins.
- Cash and cash equivalents were $70.8 million at year-end, up from $50.4 million; working capital was $61.7 million, up from $46.4 million.
- No debt was outstanding at year-end. The company had a $60 million revolving credit facility, expiring April 2016, and reported compliance with its covenants.
- FY 2012 investing cash outflow was $8.3 million; capital expenditures were $8.4 million. Financing cash outflow was $64.5 million, including $68.3 million of share repurchases. The company repurchased and retired 1.6 million shares during the year.
Material changes and business developments
- Asia Pacific sales increased 17.0% to $404.4 million, or 62.3% of company sales. Greater China rose 15.0% to $235.6 million; Southeast Asia Pacific rose 25.3% to $139.7 million. North America/Europe increased 3.4% to $244.3 million, while North Asia declined 0.6% to $29.1 million.
- Growth reflected higher active Associate counts in several regions, 2012 price increases in certain Asia Pacific markets, pre-increase buying, promotions, and new market contributions. Management estimated price increases added $17–18 million to annual sales, pre-increase buying added $11 million, and a short-term promotion added nearly $4 million.
- Active Associates increased 11.3% to 247,000; active Preferred Customers remained at 64,000. North America/Europe active Associates were flat at 78,000, while Greater China and Southeast Asia Pacific grew.
- USANA began operations in Thailand, France, and Belgium in 2012. After year-end, it received direct-selling licenses for Jiangsu, Shaanxi, and Tianjin, in addition to Beijing.
- FY 2012 effective tax rate was 32.5%, versus 34.5% in 2011, helped by tax adjustments and benefits associated with Hong Kong and Singapore operations.
Outlook, risks, and notable items
- Management’s 2013 priorities are growing active Associates, returning North America to growth, expanding Greater China, and continuing international expansion. It planned to open another market in 2013.
- Management expected 2013 gross margins to decline further, partly from a pricing initiative in mature markets and shifts in geographic sales mix. Price reductions began in several markets in January 2013 and may pressure near-term sales and earnings. Associate incentives were expected to decline modestly to about 42.5% of sales.
- Planned 2013 capital expenditures were $20–25 million, primarily for China and international development. Management believed cash, operating cash flow, and available credit would meet ordinary foreseeable needs.
- Key exposures include dependence on independent distributors and retention of key leaders; intense competition; foreign-exchange movements; product, advertising, and direct-selling regulation; and the legal and licensing environment in China. Hong Kong represented 27.9% of 2012 sales, creating concentration and transition risk as the company seeks China growth.
- The filing cites false and misleading statements about the company in November 2012 that affected Associate confidence and the share price. Management said it was not then engaged in legal proceedings expected to materially harm the business; routine litigation and disputes remain possible.
- No goodwill impairment was recorded. However, the Sensé reporting unit’s estimated fair value exceeded carrying value by only about 1%, making the valuation sensitive to assumptions. Management assessed internal controls as effective, and the auditor issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended period: this is a FY 2012 annual report, not a 2011 Q4 filing.
- Track whether active Associate growth—especially in North America—and China sales growth continue, and whether new licenses and product approvals support expansion.
- Assess the actual effects of 2013 price reductions on sales volume, gross margin, and Associate retention.
- Review cash generation against the $20–25 million capital-spending plan and continued repurchases; the filing provides no numerical 2013 sales or EPS guidance.
- Monitor Hong Kong sales concentration, China regulatory compliance and licensing, currency exposure, and the narrow Sensé goodwill valuation headroom.